Thank you, Mr. Chair.
I'd like to thank Mr. Affleck, Mr. Prouse and Mr. Curran, who took the time out of their busy schedules to spend some time with us today.
Mr. Affleck, on the regulatory framework you guys are working on with gene editing—and Mr. Blois touched on that—the international partners are used to another regulatory framework, and in Canada, we're essentially based on outcome: whether or not it's safe.
With your dealings with U.S. companies and others, is that, within itself, creating a barrier, or is that helping?